Frederick Haraka

In the News

‘Let’s do more to end malaria for good’

Dar es Salaam, November 29, 2017. Ifakara Health Institute (IHI) Chief Executive Director (CED), Dr. Honorati Masanja, has challenged scientists and other partners in the global fight against malaria to …

Joint statement: Scientists update on residual malaria situation

Dar es Salaam, November 29, 2017. The Residual Malaria Transmission workshop enters the second day today. The workshop, which is scheduled to end tomorrow, discusses findings of research projects investigating …

Recent Projects

Understanding and enhancing approaches to quality improvement in small and medium sized private facilities in sub-Saharan Africa

This is an evaluation study that IHI is conducting in collaboration with London school of hygiene and tropical medicine. The research takes place in the context of an innovative intervention …

Vaccine Delivery Costing Study

As countries drive towards achieving high and equitable coverage of life-saving vaccines, the availability of sustainable, equitable, and predictable financing for vaccine delivery is essential. Over the last two decades, …

Frederick Haraka

Research Scientist

Dr. Frederick Haraka is a research scientist at Ifakara Health Institute, working within the Tuberculosis research group. Prior to joining the institute in 2010, Dr. Haraka obtained his Medical Degree from the Muhimbili University of Health and Allied sciences, Tanzania, in 2009, and in 2013 received his Master’s degree in Applied Epidemiology from the University of Nottingham in the UK, with merit. He is currently registered as a PhD candidate in Epidemiology at the Swiss Tropical and Public Health institute, University of Basel in Switzerland. Dr. Haraka has experience in leading and implementing Good Clinical Practice (GCP), regulated clinical trials of Tuberculosis treatment regimen, vaccines and diagnostics. He is also actively involved in designing, implementing and analysing observational studies in TB and HIV. Following this interest, Dr. Haraka has numerous publications in both local and international journals focused around issues on TB and HIV. Dr. Haraka is currently a site Principal Investigator, leading a phase 2 multi-centre TB treatment regimen trial funded and sponsored by Global alliance for tuberculosis drug development, titled “A Phase 2 Open‐Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide during 8 weeks of treatment in Adult Subjects with Newly Diagnosed Drug‐Sensitive or Multi Drug‐Resistant, Smear‐Positive Pulmonary Tuberculosis”. Beyond his scientific research, Dr Haraka is a part-time lecturer at International Medical and Technological University and Hubert Kairuki Memorial University, and mentor to junior researchers in the Institutes TB research group.

View Dr. Haraka’s Research Interests & Publications


Evaluation of Cepheid GeneXpert Omni combined with the Xpert MTB/RIF Ultra in Primary Health Care in Tanzania

Evaluation of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide for treatment of newly-diagnosed TB patients

Tanzania lung health study: prevalence and risk of chronic obstructive pulmonary disease

Evaluation of efficacy, safety and tolerability of a three-drug regimen (Moxifloxacin+PA‐824+Pyrazinamide) for TB and MDR-TB

© Ifakara Health Institute (IHI), 2016